Literature DB >> 10577931

Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2.

J L Hopper, M A Jenkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577931      PMCID： PMC1288387          DOI： 10.1086/302674

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN： 0002-9297            Impact factor:   11.025


× No keyword cloud information.
  7 in total

1.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

2.  The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

Authors:  P Hartge; J P Struewing; S Wacholder; L C Brody; M A Tucker
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

3.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.

Authors:  J Peto; N Collins; R Barfoot; S Seal; W Warren; N Rahman; D F Easton; C Evans; J Deacon; M R Stratton
Journal:  J Natl Cancer Inst       Date:  1999-06-02       Impact factor: 13.506

4.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Authors:  F J Couch; M L DeShano; M A Blackwood; K Calzone; J Stopfer; L Campeau; A Ganguly; T Rebbeck; B L Weber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

5.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

6.  Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

Authors:  J L Hopper; M C Southey; G S Dite; D J Jolley; G G Giles; M R McCredie; D F Easton; D J Venter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-09       Impact factor: 4.254

7.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Authors:  D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272
  7 in total
  4 in total

1.  The effect of disease penetrance, family size, and age of onset on family history with application to setting eligibility criteria for genetic testing.

Authors:  Alexandre Sibert; David E Goldgar
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

2.  Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.

Authors:  Rodrigo Santa Cruz Guindalini; Andrew Song; James D Fackenthal; Olufunmilayo I Olopade; Dezheng Huo
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

3.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.

Authors:  P Vahteristo; H Eerola; A Tamminen; C Blomqvist; H Nevanlinna
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

4.  Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).

Authors:  Carmel Apicella; Lesley Andrews; Shirley V Hodgson; Sheila A Fisher; Cathryn M Lewis; Ellen Solomon; Katherine Tucker; Michael Friedlander; Agnes Bankier; Melissa C Southey; Deon J Venter; John L Hopper
Journal:  Breast Cancer Res       Date:  2003-08-28       Impact factor: 6.466
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.